Stockscreener 앱 받기
30.73
0.49%
0.15
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $38 to $67 - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX) - Stock Titan
Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1 - Stock Titan
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High? - Eastern Progress
Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup - ChartMill
CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals - Yahoo Finance
State Street (CLDX) reports 2.8M shares, 4.2% stake in CELLDex Therapeutics - Stock Titan
The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Q1 Loss And Barzolvolimab Milestones - Sahm
LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67 - Moomoo
RLAY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Weighing Celldex Therapeutics (CLDX) Valuation As Price-To-Book And DCF Send Mixed Signals - Sahm
Celldex (CLDX) Receives a Buy from Barclays - The Globe and Mail
Celldex Therapeutics Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga
Celldex: Q1 Earnings Snapshot - theheraldreview.com
MSN Money - MSN
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Celldex filled two late-stage hives trials 6 months early - Stock Titan
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, vs. FactSet Est of $795K - marketscreener.com
Celldex Therapeutics (NASDAQ: CLDX) widens loss while funding late-stage barzolvolimab trials - Stock Titan
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, Vs. FactSet Est of $795K - Moomoo
Celldex (NASDAQ: CLDX) Q1 loss grows while $345M raise funds pipeline - Stock Titan
Celldex Reports First Quarter Financial Results and Provides Corporate Update - ChartMill
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial (NASDAQ:CLDX) - Seeking Alpha
FMR LLC reports 5.6% stake in CellDex Therapeutics (CLDX) - Stock Titan
Wall Street analysts see a 76.42% upside in Celldex (CLDX): Can the stock really move this high? - MSN
Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Asthma Pipeline Enters a New Era of Precision Respiratory Care with 100+ Therapies and 80+ Companies Advancing Next-Generation Biologics and Small Molecules | DelveInsight - Barchart.com
Celldex earnings on deck as barzolvolimab Phase 3 nears readout By Investing.com - Investing.com Australia
Vanguard Capital Management (NASDAQ: CLDX) reports 3.45M shares; 5.17% stake - Stock Titan
Celldex earnings on deck as barzolvolimab Phase 3 nears readout - Investing.com UK
[ARS] Celldex Therapeutics, Inc. SEC Filing - Stock Titan
Celldex (NASDAQ: CLDX) sets 2026 virtual meeting, seeks approval for equity plan - Stock Titan
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
Celldex Therapeutics announces public offering of common stock - MSN
Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving AverageWhat's Next? - MarketBeat
Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump - Yahoo Finance
Is Celldex (CLDX) stock a strategic buy | Q4 2025: EPS Misses ViewsCommunity Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Celldex (CLDX) Operational Review | Q4 2025: Earnings UnderperformPrice Target - Cổng thông tin điện tử tỉnh Lào Cai
2.98%
1.33%
자본화:
|
볼륨(24시간):